500 Boylston Street, 11th Floor
Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin-4 (MC4) receptor agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project(www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts.
Founder: Bart Henderson
CEO: Keith M. Gottesdiener
CMO: Fred T. Fiedorek
CSO: Lex H.T. Van der Ploeg
Please click here for.
Please click here for clinical trial information.